31 results about "Plasma Metabolism" patented technology

The invention discloses a lung cancer early diagnostic marker based on metabonomics and a screening method thereof. The diagnostic marker comprises any one or combination of various markers in 25 plasma metabolism markers. The invention also provides a method for establishing a diagnostic model through utilization of the lung cancer early diagnostic marker and application of the lung cancer earlydiagnostic marker in a diagnostic kit. According to the lung cancer early diagnostic marker, the methods and the application, through utilization of a high performance liquid chromatography-mass spectrometry, non-target metabonomics analysis is carried out on plasma of patients; through utilization of an artificial intelligence data analysis technology, different metabolite between lung cancer patients and normal people is discovered; and further through target metabonomics analysis and machine learning modeling, diagnostic capability of specificity different metabolite, namely, the lung cancer early diagnostic marker in lung cancer early diagnosis is verified.

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

The invention discloses a plasma metabolism marker related to diagnosis of tourette syndrome (TS) of children and an application thereof. The marker is L-arginine and D-piperidine acid. The marker isused for diagnosing the attack risk of TS of children from the perspective of metabolites, the result is accurate, objective and reliable, the TS group and the normal group can be well distinguished,the TS occurrence risk can be accurately and sensitively evaluated, only a blood sample needs to be provided, other tissue samples are not needed, the possibility and feasibility of clinical application are greatly improved, and a guidance basis is provided for a clinician to make an early diagnosis and intervention scheme.

The invention discloses a group of plasma metabolism markers related to intracranial aneurysm and application of the plasma metabolism markers. The markers comprise oxidized glutathione, reduced glutathione, methyl beta-D-galactopyranoside, koji disaccharide, D-pinose, dopaquinone, indoleacetaldehyde, 5, 5 '-dihydroxyacetophenone, beta-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl The reagent is prepared from 2, 6-dimethylbenzimidazole, N-palmitoyl glycine, uracil, indole-3-acetic acid and 1-acetyl indole. According to the invention, the plasma is used as a detection object, and the sample is noninvasive and easier to obtain, can be used for large-scale screening, is beneficial to early diagnosis and dynamic monitoring of intracranial aneurysm, and reduces huge risks brought to patients by rupture of intracranial aneurysm; small molecule metabolites are used as diagnostic markers, and the detection method is simple, can be used in the field of rapid diagnosis, and is good in detection specificity and high in accuracy; compared with protein and gene as disease diagnosis markers, the method has superiority.

The invention discloses a blood plasma metabolic marker related to the diagnosis of Tourette syndrome (TS) in children and its application. The markers are L-arginine and D-pipericolic acid. The markers of the present invention can diagnose the risk of TS in children from the perspective of metabolites, and the results are accurate, objective and reliable, can well distinguish the TS group from the normal group, can accurately and sensitively evaluate the risk of TS, and only need to provide blood samples It can be carried out without other tissue samples, greatly improving the possibility and feasibility of clinical application, and providing guidance for clinicians to formulate early diagnosis and intervention plans.

The invention provides a plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application of the plasma metabolism marker combination, and metabolism markers are selected from N-acetylphenylalanine, 1, 7-dimethylxanthine, 8, 7-dimethylxanthine, 8, 7-dimethylxanthine, 8, 7-dimethylxanthine and 8, 7-dimethylxanthine. The composition is one or a combination of more of 1, 15-dihydroxy eicosatetraenoic acid, N-acetyl-5-methoxytryptamine, 2-amino-4-hydroxy pteridine, 5-hydroxytryptamine, lysophosphatidylcholine (15: 0), methylmaleic acid, N-methyl-alpha-aminoisobutyric acid and thymine. The ten metabolic markers provided by the invention can accurately diagnose colorectal cancer, have high sensitivity and strong specificity, can replace the existing method for diagnosing colorectal cancer based on blood and excrement detection, reduce trauma and missed diagnosis rate, reduce detection cost, and have clinical use and popularization values.

Based on the plasma metabolomics research of patients with different molecular subtypes of breast cancer, the present invention finds biomarkers that can be used to distinguish Luminal B type vs HER2 overexpression type, Luminal A type vs Basal-like breast cancer. Compared with the HER2 overexpressing type, the plasma levels of proline, isoleucine, leucine, 2-octenedioic acid and valine in Luminal B patients were significantly up-regulated, and pipecolic acid was significantly down-regulated; Compared with Luminal A type, the content of valine in the plasma of patients with LuminalA type was significantly up-regulated, while pipecolic acid, glycine, glycochenodeoxycholic acid and palmitic acid were significantly down-regulated. The invention can rapidly predict the molecular subtype of breast cancer, and provides an important basis for clinical diagnosis, treatment and prognosis evaluation of breast cancer.

The invention discloses a method for analyzing plasma metabolomics of patients with primary osteoporosis based on sleep disorders. The samples are prepared and collected from the plasma samples of primary osteoporosis patients with sleep disorders treated by sleep cognitive behavior. Then prepare for ultra-high performance liquid chromatography-mass spectrometry detection and analysis; sleep disorders are determined according to the Pittsburgh sleep quality index scale; ultra-high performance liquid chromatography-mass spectrometry detection and analysis: serum samples are separated by chromatographic columns and analyzed by mass spectrometry; data analysis Extract and align the original data of the instrument to obtain data that is free from noise interference and can be used for statistical analysis. Analyze the data through orthogonal partial least squares discriminant analysis and paired sample T test to obtain the differential metabolites between the two groups, and Preliminary identification and verification of these substances combined with existing literature reports. The present invention provides favorable technical support for the early prediction and prognosis of patients with primary osteoporosis in sleep disordered groups.

The invention belongs to the technical field of biomedicine, and specifically relates to a plasma metabolic marker for distinguishing benign and malignant ovarian tumors and an application thereof. The present invention provides a new combination of plasma diagnostic markers for distinguishing benign and malignant (borderline + malignant) ovarian tumors, and can also be used to distinguish benign and early malignant ovarian tumors (borderline + malignant), with high accuracy and sensitivity High characteristics, the AUC of the training set reached 0.876, and the AUC of the verification set was 0.896. The AUC of the early diagnosis training set is 0.847, and the AUC of the verification set is 0.988, which is better than that of CA125 (AUC: training set: 0.733; verification set: 0.893). The marker combination belongs to plasma small molecule metabolites and has the advantage of being non-invasive.

The invention discloses a metabolomics-based diagnostic marker for pancreatic cancer and a screening method thereof. The diagnostic marker comprises any one or a combination of 31 plasma metabolic markers. The present invention also provides a method for constructing a diagnostic model using the pancreatic cancer diagnostic marker and its application in a diagnostic kit. The present invention conducts non-target metabolomics analysis on patient plasma through high-performance liquid chromatography-mass spectrometry technology, discovers differential metabolites between pancreatic cancer patients and normal people through artificial intelligence data analysis technology, and further analyzes target metabolomics and Machine learning modeling verifies the diagnostic ability of the specific differential metabolites, namely pancreatic cancer diagnostic markers, in the diagnosis of pancreatic cancer.

The invention discloses a group of plasma metabolism micromolecular markers related to lung cancer early diagnosis and an application thereof. The plasma metabolism micromolecular markers comprise oneor more of the following markers: propionic acid, aspartic acid, furan glucoside, citric acid, allose, talose, galactopyranose, pyruvic acid, tryptophan, leucyl proline, glyceryl phosphoryl choline,oleoyl carnitine, lysophosphatidyl choline (18:3), lysophosphatidyl choline (18:2), lysophosphatidyl choline (18:1), lysophosphatidyl choline (22:6), lysophosphatidyl ethanolamine (20:0), lysophosphatidyl ethanolamine (18:2), and complex aminoacyl valine. Compared with the traditional protein biomarkers, the group of the provided markers has the stronger outcome relevance with diseases, and is stable, minimally invasive, and easy to detect, capable of greatly improving the sensitivity and the specificity of the related disease diagnosis, and suitable for the early clinical diagnosis and monitoring of lung cancer.

The invention belongs to the field of medical biotechnology and relates to the application of plasma metabolic markers in diagnosing or monitoring HBV. The object of the present invention is to provide the application of the metabolic marker in the blood in the preparation diagnosis or the reagent of monitoring hepatitis B virus, wherein, said marker is Creatinine, L-Proline, L-Arginine, PC (P-16: 0 / 20:4(8Z, 11Z, 14Z, 17Z)), PE(18:2(9Z, 12Z) / 18:1(9Z)), PC(o‑16:1(9Z) / 18:2( 9Z,12Z)), PC(P-16:0 / 18:1(11Z)), PE(18:2(9Z,12Z) / 18:0), PE(P-16:0 / 22:4( 7Z,10Z,13Z,16Z)), PE(P-16:0 / 22:4(7Z,10Z,13Z,16Z)), PE(P-18:0 / 18:2(9Z,12Z)), PE(18:0 / 18:1(11Z)), LysoPE(18:0 / 0:0), PE(16:0 / 18:1(11Z)), or PE(18:2(9Z, 12Z) / 16:0).

The invention discloses a quantity spectrum chip for calibrating quantitative analysis of metabolome, the chip comprises a mixed isotope internal standard composition for calibrating non-targeted plasma metabolome data, and the composition is composed of 64 substances. According to the invention, different proportions of the mixed isotope internal standard are researched to calibrate the blood plasma endogenous metabolite spectrum data; it is found that the combination rule of the minimum RSD value can be obtained by flexibly matching the endogenous metabolite in the plasma with the isotope internal standard of the endogenous metabolite, the isotope internal standard of the same type, the isotope internal standard close to the retention time and the isotope internal standard close to the mass spectrum signal intensity.

The invention concretely relates to a method for simultaneously detecting paracetamol and its eight blood plasma metabolites. An experiment result shows that the method allows the lower quantification limit of the paracetamol and its eight blood plasma metabolites to reach 0.46 ng / mL, and the correlation coefficient of every linear regression equation is 0.998; the intra-day accuracy of all detected substances is 85-111%, and the precision is lower than 9%; and the inter-day accuracy of all the detected substances is 94-108%, and the precision is lower than 9%. The method is fast, sensitive and accurate, and is suitable for quantitatively detecting the paracetamol and its eight blood plasma metabolites in rat blood plasma.

The invention relates to a cholelithiasis related blood plasma metabolism micro-molecular marker and an application thereof. The marker is trimethylamine oxide and trimethylamine. Metabolism micro-molecules of normal contrast blood plasma and cholelithiasis patient's blood plasma are compared through adopting UPLC-Q exactive MS to find the blood plasma metabolism micro-molecular marker combination used for assessing that whether a patient is suffering from cholelithiasis and having diagnosis values in the blood plasma. A cholelithiasis diagnosing and monitoring kit convenient for clinic application is developed through applying the UPLC-Q exactive MS detected by the blood plasma metabolism micro-molecular marker.

The invention discloses application of new interaction of plasma metabolism in skin microflora of a psoriasis patient. The application comprises collection of patient group information and healthy control group information, sample collection, microbiome DNA extraction and 16S sequencing, 16S sequencing data analysis, LC-MS metabonomics data collection, GC-MS data collection, and metabonomics data analysis and statistical analysis by utilizing LC-MS and GC-MS. The skin microbiome 16S sequence and the plasma metabonomics data are integrated, the change of the global metabolism steady state of the psoriasis patient and the relationship between the global metabolism steady state and the skin microflora are disclosed, and the application of the new interaction of the plasma metabolism in the key skin microflora in the psoriasis pathogenesis is disclosed. The data provided by the invention provides a potential mechanism for the skin microbiota of the psoriasis patient to regulate blood metabolism, which is helpful for further understanding the pathological mechanism of psoriasis.